SCHEMBL23635946

SCHEMBL23635946

COc1ccc(Cl)c(-c2nnc(NC(=O)OC(C)(C)C)s2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.55
NPC1 O15118 6/20 0.55
ALDH1A1 P00352 4/20 0.55
HPGD P15428 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
HSD17B10 Q99714 4/20 0.55
TP53 P04637 2/20 0.55
PKM P14618 1/20 0.55
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
RAB9A P51151 6/20 0.51
MAPT P10636 4/20 0.51
KMT2A Q03164 2/20 0.51
RXFP1 Q9HBX9 2/20 0.49
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.46
NPSR1 Q6W5P4 2/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27097771 0.87 KDM4E (0.56) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL23292566 0.84 NPC1 (0.54) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL23635936 0.84 NPC1 (0.49) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL30842110 0.84 NPC1 (0.49) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL27097742 0.78 KDM4E (0.58) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL14598625 0.75 TDP1 (0.51) KDM4EALDH1A1MAPTKMT2AMEN1
SCHEMBL30842121 0.74 KDM4E (0.53) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL27097750 0.74 KDM4E (0.53) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL23635944 0.73 KDM4E (0.53) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL30842118 0.73 KDM4E (0.44) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240277683-A1 COMPOUNDS CTXT PTY LTD (AU) 2024-08-22 US disclosed
US-11911372-B2 Compounds CTXT PTY LTD (AU) 2024-02-27 US disclosed
US-11911372-B2 Compounds CTXT PTY LTD (AU) 2024-02-27 US disclosed
US-11911372-B2 Compounds CTXT PTY LTD (AU) 2024-02-27 US disclosed
US-20210213004-A1 Compounds CTXT PTY LTD (AU) 2021-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240277683-A1 COMPOUNDS SLC10A1, ABCB11, REN KDM4E 4246/4885NPC1 9/4885ALDH1A1 951/4885
US-20210213004-A1 Compounds SLC10A1, ABCB11, REN KDM4E 3932/4885NPC1 13/4885ALDH1A1 744/4885
US-11911372-B2 Compounds SLC10A1, ABCB11, REN KDM4E 3932/4885NPC1 13/4885ALDH1A1 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.